エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 27, 2025
WELLGISTICS HEALTH, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-42530 | 93-3264234 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
3000 Bayport Drive
Suite 950
Tampa, FL 33607
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (844) 203-6092
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock, $0.0001 par value per share | WGRX | The Nasdaq Capital Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On October 27, 2025, Wellgistics Health, Inc. (the “Registrant”) issued a press release, a copy of which is furnished as Exhibit 99.1 hereto.
The information in this Item 7.01, including Exhibits 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Report will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibits 99.1.
The press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. With the exception of historical matters, the matters discussed in the press releases include forward-looking statements within the meaning of applicable securities laws. Such forward-looking statements include, among others, statements regarding the Company’s projects, potential financial performance, and growth opportunities. The words “believes,” “expects,” “intends,” “plans,” “anticipates,” “hopes,” “likely,” “will,” and similar expressions are intended to identify certain of these forward-looking statements. These statements are based on the Company’s expectations and involve risks, uncertainties and other important factors that could cause the actual results performance or achievements of the Company (or entities in which the Company has interests), or industry results, to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause the Company’s actual future results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors could arise. Certain risks regarding the Company’s forward-looking statements are discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”), including an extensive discussion of these risks in the Company’s Registration Statement on Form S-1, declared effective by the SEC on September 25, 2025. Readers are cautioned not to place undue reliance on these forward-looking statements which reflect management’s view only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions or circumstances.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are filed as part of, or incorporated by reference into, this Report.
| Exhibit No. | Description | |
| 99.1 | Press Release Dated October 27, 2025 | |
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 27, 2025 | WELLGISTICS HEALTH, INC. | |
| By: | /s/ Prashant Patel | |
| Prashant Patel, President | ||
Exhibit 99.1
Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain™ Manufacturer-to-Patient Blockchain-enabled Tracking & Dispensing Platform for Prescription Drug Market
Powered by DataVault AI’s High-Performance Computing & Information Exchange, Data Monetization for Traditional and Compound Pharmacies is Set to Become a Reality in the $639 Billion Prescription Drug Market, with Beta Testing Expected in First Half of 2026
TAMPA, FL, and PHILADELPHIA, PA October 27, 2025 – Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ: WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a software as a service (SAAS) agreement with DataVault AI, Inc. (“DataVault”) (NASDAQ: DVLT) , a pioneering technology company leading the way in AI data experience, valuation, and monetization, to begin the development of manufacturer-to-patient blockchain-enabled smart contracts (“PharmacyChain™”) being designed to optimize Wellgistics’ proprietary technology and physical infrastructure for the prescription drug industry. The companies expect to finalize the related profit-sharing license agreement in the fourth quarter of 2025, once all various potential revenue streams stemming from the partnership are identified and valued.
“In just the last few days, we have already received significant inbound interest from manufacturers, pharmacists and insurers who see the significant benefit in being able to reliably close the loop on prescriptions reaching pharmacies, pharmacies rapidly qualifying them for optimized insurance reimbursement and physicians receiving confirmation that patients actually receive their prescribed pharmaceutical regimens,” said Prashant Patel, RPh, President & Interim-CEO of Wellgistics. “We are making the integration of smart contracts a central pillar for our growth strategy going forward, allowing us to differentiate ourselves in the traditional pharmaceutical distribution and compound pharmacy spaces. We expect PharmacyChain to allow us to gain market share in the markets we are already in, as well as expand into new markets. Beta testing for PharmacyChain is expected to begin in the first half of 2026.”
DataVault AI’s Web 3.0 platform provides a proprietary IP and unique value proposition within the pharmaceutical distribution, pharmaceutical manufacturer and compound pharmacy spaces. The patent protected technology, enabled by breakthrough smart contracts, will allow pharmacies to securely and seamlessly receive and transfer data that will allow pharmacists to more easily make appropriate drug dispending decisions for the benefit of patients and insurers.
Patents that cover DataVault AI’s blockchain and secure token driven data scoring, valuation, visualization and monetization on its patented Information Data Exchange® include, but are not limited to:
| ● | U.S. Patent 12,100,025 entitled “Platform for Management of User Data,” issued on September 24, 2024; |
| ● | U.S. Patent 11,960,622 entitled “Blockchain and secure token driven data scoring, valuation, visualization and monetization,” issued on April 16, 2024; |
| ● | U.S. Patent 12,020,787 entitled “Triggered Responses to Real-time Electroencephalography,” issued on June 25, 2024. |
PharmacyChain is also expected to allow manufacturers to better understand their key constituents, physicians and patients, in order to make more personalized sales and marketing campaigns, as well as potentially expand upon the recent trend of direct-to-consumer cash sales. As part of Wellgistics’ desire to help improve patient outcomes, it also intends to ultimately include diagnostic and biometric data, on an opt-in basis, to help further empower healthcare professionals and patients with data-driven recommendations based on gold-standard best practices from leading physicians who leverage the power of biomarker and biometric data to help optimize health outcomes for their patients.
“We are excited to assist Wellgistics in developing new additive revenue streams within the $639 billion prescription drug market,” said Nathaniel Bradley, President & CEO of DataVault AI. “Wellgistics has positioned themselves at the intersection of physical and technology infrastructure in the pharmacy business. Our DataVault AI team will develop Digital Twins of pharmaceutical logistics, delivery systems and patients. Utility tokens will ensure that every medicine you are prescribed will also be accompanied by recommendations to optimize its use for your body by tailoring lifestyle and nutritional recommendations based upon your own personal health profile, on a consented ‘opt-in’ basis. The objective is to align prescribed medicines with increasingly commonplace wellness regimens, rooted in sound science and personal biomarker and biometric data obtained from the increasing use of wearable devices, which have demonstrated improved outcomes in well controlled studies. Previously this was an overwhelming task, however with our technology we can make this commonplace in healthcare’s emerging high performance, data-driven era.”
About Wellgistics Health, Inc.
Wellgistics Health (NASDAQ: WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.
For more information, visit www.wellgisticshealth.com.
About DataVault AI Inc.
DataVault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.
Wellgistics Health Media & Investor Contact
Media:
media@wellgisticshealth.com
Investor Relations:
IR@wellgisticshealth.com
Wellgistics Health Investor Relations Contact
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com
DataVault AI Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
DataVault AI Media Contact:
marketing@dvlt.ai